Franklin Templeton, Inc. and related reporting persons filed an amended Schedule 13G with the SEC on October 28, 2026, disclosing beneficial ownership in Adicet Bio, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Franklin Templeton, Inc. and its reporting group collectively reported 724,138 shares of Adicet Bio common stock.
  • Percent of class: The 724,138 shares represent 7.7% of Adicet Bio's outstanding common stock class, according to the filing.
  • Sole voting and dispositive power: All 724,138 shares carry sole voting power and sole dispositive power held by Franklin Advisers, Inc., a subsidiary, per the filing.
  • Sub-fund interest: Franklin Biotechnology Discovery Fund, a sub-fund of Franklin Templeton Investment Funds (a Luxembourg Registered SICAV), holds an interest in 498,920 shares, or 5.3% of the class, according to the filing.
  • Reporting person name change: The filing notes that effective August 17, 2026, Franklin Resources, Inc. was renamed Franklin Templeton, Inc.
  • Event date: The date of the event requiring the filing is stated as September 30, 2026.

Franklin Advisers Holds Sole Control Over Adicet Bio Position

According to the amended Schedule 13G (Amendment No. 1) filed on October 28, 2026, four reporting persons disclosed their beneficial ownership in Adicet Bio, Inc. (CUSIP: 007002207): Franklin Templeton, Inc., Charles B. Johnson, Rupert H. Johnson, Jr., and Franklin Advisers, Inc. The filing states that sole voting power and sole dispositive power over all 724,138 shares rests entirely with Franklin Advisers, Inc., a California-incorporated investment adviser and subsidiary of Franklin Templeton, Inc. The other three reporting persons each reported zero shares for purposes of sole voting, shared voting, sole dispositive, and shared dispositive power.

The filing identifies Franklin Templeton, Inc. as a Delaware holding company and notes that it was formerly known as Franklin Resources, Inc. prior to a name change effective August 17, 2026. Charles B. Johnson and Rupert H. Johnson, Jr. are each reported as individual holding company persons, both U.S. citizens. Their filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

The filing further discloses that clients of the Investment Management Subsidiaries, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, "have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein." Adicet Bio, Inc. is headquartered at 131 Dartmouth Street, 3rd Floor, Boston, MA 02116, per the filing. The reporting persons are located at One Franklin Parkway, San Mateo, CA 94403-1906.

What Was Disclosed

Franklin Templeton, Inc. and affiliated reporting persons filed an amended Schedule 13G disclosing aggregate beneficial ownership of 724,138 shares, or 7.7%, of Adicet Bio, Inc. common stock as of September 30, 2026, with sole control resting with Franklin Advisers, Inc.